On May 15, 2025, RBC Capital maintained its "Outperform" rating for Ardent Health Partners, Inc. (ARDT, Financial). This decision by analyst Ben Hendrix highlights continued confidence in the company’s growth prospects despite the absence of a price target adjustment.
The price target remains steady at $21.00 USD, consistent with the previous valuation. According to RBC Capital, this price target reflects the company's stable market performance and future potential.
Investors should take note of this unchanged outlook as it suggests a sustained positive view from RBC Capital. As of now, Ardent Health Partners (ARDT, Financial) trades on the NYSE, maintaining its position as a company with promising prospects according to RBC Capital’s analysis.
